Chapter title |
Platforms for Recombinant Therapeutic Glycoprotein Production
|
---|---|
Chapter number | 1 |
Book title |
Recombinant Glycoprotein Production
|
Published in |
Methods in molecular biology, January 2018
|
DOI | 10.1007/978-1-4939-7312-5_1 |
Pubmed ID | |
Book ISBNs |
978-1-4939-7311-8, 978-1-4939-7312-5
|
Authors |
Amanda Mizukami, Angelo Luis Caron, Virgínia Picanço-Castro, Kamilla Swiech, Mizukami, Amanda, Caron, Angelo Luis, Picanço-Castro, Virgínia, Swiech, Kamilla |
Abstract |
The majority of FDA-approved biology-derived products are recombinant glycoproteins. These proteins have been used for the treatment of several diseases, with numerous products currently approved for clinical use. The choice of the expression system is a key step toward a successful functional protein production, since glycosylation influences yield, pharmacokinetics, biological activity, and immunogenicity. This chapter covers the general aspects of therapeutic recombinant glycoproteins and the platforms that are being employed for their production. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 33 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 7 | 21% |
Student > Master | 5 | 15% |
Researcher | 4 | 12% |
Student > Ph. D. Student | 3 | 9% |
Student > Doctoral Student | 2 | 6% |
Other | 3 | 9% |
Unknown | 9 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 10 | 30% |
Agricultural and Biological Sciences | 5 | 15% |
Medicine and Dentistry | 2 | 6% |
Environmental Science | 1 | 3% |
Chemical Engineering | 1 | 3% |
Other | 3 | 9% |
Unknown | 11 | 33% |